HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>We reviewed the 2021 performance and summarized the 2022 outlook for China healthcare sector.</li>
<li>We listed the 2022 high conviction ideas and mainly analyzed the industry characteristics, the business, the core competitiveness, the forecast and the concerns of related companies.</li>
<li>Overall, there are still good investment opportunities in China healthcare industry in 2022.</li>
</ul>


We reviewed the 2021 performance and summarized the 2022 outlook for China healthcare sector.
We listed the 2022 high conviction ideas and mainly analyzed the industry characteristics, the business, the core competitiveness, the forecast and the concerns of related companies.
Overall, there are still good investment opportunities in China healthcare industry in 2022.


2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Asymchem Laboratories Tianjin / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/asymchem-laboratories-tianjin-co-ltd" target="_blank" data-smartkarma-citation="entities:28265:1" rel="noopener">Asymchem Laboratories (002821 CH)</a> is a global contract development manufacturing organisation (CDMO). Asymchem is pre-marketing an H Share listing to raise $1.5 billion, according to press reports.</li>
<li>Asymchem has delivered strong growth and margin progression (on a constant currency basis) over the track record period.</li>
<li>The forward indicators suggest that the near-term prospects remain solid. Overall, we think that Asymchem has robust fundamentals.  </li>
</ul>



Asymchem Laboratories (002821 CH) is a global contract development manufacturing organisation (CDMO). Asymchem is pre-marketing an H Share listing to raise $1.5 billion, according to press reports.
Asymchem has delivered strong growth and margin progression (on a constant currency basis) over the track record period.
The forward indicators suggest that the near-term prospects remain solid. Overall, we think that Asymchem has robust fundamentals.  


Asymchem Laboratories H Share Listing: On-Demand Science

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

<ul>
<li>Asymchem Laboratories (AL) aims to raise around US$1-1.5bn in its H-share listing in Hong Kong.</li>
<li>AL is a provider of outsourced pharmaceutical development and manufacturing solutions and services. </li>
<li>In this note, we will talk about the recent updates, undertake a peer comparison and look at the likely valuations.</li>
</ul>


Asymchem Laboratories (AL) aims to raise around US$1-1.5bn in its H-share listing in Hong Kong.
AL is a provider of outsourced pharmaceutical development and manufacturing solutions and services. 
In this note, we will talk about the recent updates, undertake a peer comparison and look at the likely valuations.


Asymchem Labs A/H Listing - PHIP Updates and a Look at Valuations

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Event-Driven

<ul>
<li>As expected, <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a> replaces <a href="https://www.smartkarma.com/entities/china-evergrande-group" target="_blank" data-smartkarma-citation="entities:479:1" rel="noopener">Evergrande (3333 HK)</a> in the <a href="https://www.smartkarma.com/entities/hang-seng-china-enterprises-index" target="_blank" data-smartkarma-citation="entities:22900:1" rel="noopener">Hang Seng China Enterprises Index (HSCEI INDEX)</a> after the close of trading on 3 December.</li>
<li>Using prices from the close on 19 November to cap the stocks, estimated one-way turnover at the rebalance is 4.50% and will result in a one-way trade of HK$3,208m.</li>
<li>Short interest on <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a> is over 8 days of ADV and short covering could take the stock higher in the short-term versus its peers.</li>
</ul>


As expected, Innovent Biologics Inc (1801 HK) replaces Evergrande (3333 HK) in the Hang Seng China Enterprises Index (HSCEI INDEX) after the close of trading on 3 December.
Using prices from the close on 19 November to cap the stocks, estimated one-way turnover at the rebalance is 4.50% and will result in a one-way trade of HK$3,208m.
Short interest on Innovent Biologics Inc (1801 HK) is over 8 days of ADV and short covering could take the stock higher in the short-term versus its peers.


HSCEI Index Rebalance: No Surprises Here as Evergrande Is Deleted

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

CANbridge Pharmaceuticals / Equity Capital Markets

<ul>
<li>CANbridge, a China-based rare disease-focused biopharmaceutical company, plans to raise up to USD 200m via a Hong Kong listing.</li>
<li>We look at the company's commercialized products (Caphosol, Nerlynx, Hunterase) and the core product CAN008.</li>
<li>We provide our thoughts on the rare disease drug market in China and the company's business model.</li>
</ul>


CANbridge, a China-based rare disease-focused biopharmaceutical company, plans to raise up to USD 200m via a Hong Kong listing.
We look at the company's commercialized products (Caphosol, Nerlynx, Hunterase) and the core product CAN008.
We provide our thoughts on the rare disease drug market in China and the company's business model.


CANbridge (北海康成) Pre-IPO: Not the Cup of Tea for Secondary Market

China

WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland.  We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions. 

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Wuxi Biologics (2269 HK)

2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties

The article analyzed the 2021 review and 2022 high conviction ideas, including the industry characteristics, the business, the core...

Xinyao (Criss) Wang

Asymchem Labs A/H Listing - PHIP Updates and a Look at Valuations

Asymchem Laboratories (AL) aims to raise around US$1-1.5bn in its H-share listing in Hong Kong. In this note, we talk about recent updates, peer...

Sumeet Singh

HSCEI Index Rebalance: No Surprises Here as Evergrande Is Deleted

Innovent Bio will join the HSCEI after the close on 3 Dec while Evergrande will be deleted, no surprises. One-way turnover is 4.5% due to capping &...

Brian Freitas

CANbridge (北海康成) Pre-IPO: Not the Cup of Tea for Secondary Market

CANbridge is seeking a USD 200m listing in Hong Kong. We look at CANbridge's commercialized products (Caphosol, Nerlynx, Hunterase) and the core...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties

The article analyzed the 2021 review and 2022 high conviction ideas, including the industry characteristics, the business, the core...

Xinyao (Criss) Wang

Asymchem Laboratories H Share Listing: On-Demand Science

Asymchem is pre-marketing an H Share listing to raise $1.5 billion, according to press reports. The forward indicators suggest that the near-term...

Arun George

Asymchem Labs A/H Listing - PHIP Updates and a Look at Valuations

Asymchem Laboratories (AL) aims to raise around US$1-1.5bn in its H-share listing in Hong Kong. In this note, we talk about recent updates, peer...

Sumeet Singh

HSCEI Index Rebalance: No Surprises Here as Evergrande Is Deleted

Innovent Bio will join the HSCEI after the close on 3 Dec while Evergrande will be deleted, no surprises. One-way turnover is 4.5% due to capping &...

Brian Freitas

CANbridge (北海康成) Pre-IPO: Not the Cup of Tea for Secondary Market

CANbridge is seeking a USD 200m listing in Hong Kong. We look at CANbridge's commercialized products (Caphosol, Nerlynx, Hunterase) and the core...

Ke Yan, CFA, FRM